Actively Recruiting
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
Led by Second Xiangya Hospital of Central South University · Updated on 2025-02-25
750
Participants Needed
1
Research Sites
447 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer. The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received the first-line therapy or neoadjuvant therapy of ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early small-cell lung cancer (SCLC) receiving surgery.
CONDITIONS
Official Title
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically confirmed non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) depending on cohort
- Unresectable locally advanced, metastatic, or recurrent stage IIb-III for NSCLC or stage II-III for SCLC based on AJCC TNM staging 8th edition (for advanced cohorts)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- No prior systemic treatments such as chemotherapy, anti-angiogenic drugs, targeted drugs, or immunotherapy
- At least one measurable lesion per RECIST 1.1 criteria (for applicable cohorts)
- Receiving PD-1/PD-L1 inhibitor monotherapy or combined with chemotherapy (for applicable cohorts)
- Resectable clinical stage IB-IIIB NSCLC and cardiopulmonary function suitable for surgery (for neoadjuvant cohort)
- Early-stage NSCLC IA-IIIA with available tumor tissue samples and receiving radical surgery (for surgery cohort)
- Informed consent to participate in the study
You will not qualify if you...
- Presence of EGFR-sensitizing mutation, ALK gene fusion, or ROS1 fusion (for relevant cohorts)
- Diagnosis of other malignant tumors within the past 3 years
- Concurrent acute or chronic psychiatric disorders
- Currently receiving anti-depressive or anti-anxiety therapy
- Prior participation in other clinical drug trials
- Symptomatic brain metastasis (for applicable cohorts)
- Inability to participate in psychological scale assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Oncology, The Second Xiangya Hospital, Central South University
Changsha, Hunan, China, 410011
Actively Recruiting
Research Team
F
Fang Wu, MD. PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here